The Evidence for the Use of Recombinant Human Activated Factor VII in the Treatment of Bleeding Patients With Quantitative and Qualitative Platelet Disorders
- 31 July 2007
- journal article
- review article
- Published by Elsevier BV in Transfusion Medicine Reviews
- Vol. 21 (3), 223-236
- https://doi.org/10.1016/j.tmrv.2007.03.003
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunizationAmerican Journal of Hematology, 2006
- Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet‐enhancing treatmentTransfusion Medicine, 2005
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity-a rebuttalJournal of Thrombosis and Haemostasis, 2005
- Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet countJournal of Thrombosis and Haemostasis, 2005
- Recombinant Factor VIIa in Management of Spontaneous Subcapsular Liver Hematoma Associated With PregnancyObstetrics & Gynecology, 2004
- Use of Recombinant Factor VIIa for Bleeding in Children with Glanzmann ThrombastheniaPediatric Hematology and Oncology, 2003
- Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical DevelopmentSeminars in Thrombosis and Hemostasis, 2001
- Off-label use of recombinant factor VIIa in patients following bone marrow transplantationBone Marrow Transplantation, 2001
- Unique Pathway of Thrombin-induced Platelet Aggregation Mediated by Glycoprotein IbPublished by Elsevier BV ,2001
- Antibody Removal Therapy Used Successfully at Delivery of a Pregnant Patient with Glanzmann's Thrombasthenia and Multiple Anti‐Platelet AntibodiesVox Sanguinis, 1991